Immunohistochemistry-Frozen: VEGFR3/Flt-4 Antibody (AFL4) [Alexa Fluor® 488] [NBP1-43259AF488] - VEGFR-3 (green) was detected in murine cancer using VEGFR-3-AlexaFluor488 antibody (1:50; 1 hour) in PBS. Nuclei were ...read more
Alexa Fluor (R) products are provided under an intellectual property license from Life Technologies Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: (i) in manufacturing; (ii) to provide a service, information, or data in return for payment; (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com. This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.
Alternate Names for VEGFR3/Flt-4 Antibody (AFL4) [Alexa Fluor® 488]
EC 2.7.10
EC 2.7.10.1
FLT4
Flt-4
fms-related tyrosine kinase 4
LMPH1A
PCLFLT41
soluble VEGFR3 variant 1
soluble VEGFR3 variant 2
soluble VEGFR3 variant 3
Tyrosine-protein kinase receptor FLT4
vascular endothelial growth factor receptor 3
VEGF R3
VEGFR3
VEGFR-3
VEGFR3Fms-like tyrosine kinase 4
Background
FLT4, a VEGF Receptor type protein kinase, is an endothelial cell-specific receptor. Binding of the extracellular domain of FLT4 to the vascular endothelial growth factor-related protein VEGF-C stimulates tyrosine phosphorylation and mitogenesis of endothelial cells. FLT4 (-/-) mice have been shown to have defective blood vessel development in early embryos and to experience cardiovascular failure at embryonic day 9.5. A mutation in the FLT4 gene has been implicated in human hereditary lymphedema type I. Similarly, a mutation in the conserved catalytic domain of FLT4, in close proximity to the FLT4 mutations in human primary lymphedema, has been linked to the Chy mouse mutant.
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.